ફેફસાનું કેન્સર (non-small cell)
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
ક્યાં જવું
ભારતમાં 13 hospitals આ trial માટે દર્દીઓને લઈ રહ્યા છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
સ્પોન્સર: મિરાતી થેરાપ્યુટિક્સ ઇન્ક.
ClinicalTrials.gov પર NCT04613596
રજિસ્ટ્રીમાં છેલ્લે 13 Oct 2026 ના રોજ અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું